Suh Beomseok, Yun Jae Moon, Park Sehhoon, Shin Dong Wook, Lee Tae Hoon, Yang Hyung-Kook, Ahn Eunmi, Lee Hyejin, Park Jin Ho, Cho BeLong
Department of Family Medicine & Health Promotion Center, Seoul National University Hospital, Seoul, Republic of Korea.
Division of Hematology & Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Cancer. 2015 Nov 1;121(21):3818-25. doi: 10.1002/cncr.29577. Epub 2015 Jul 15.
Although heavy alcoholics are at heightened risk for hepatocellular carcinoma (HCC), there are no guidelines that recommend HCC screening for heavy alcoholics. This study investigated FIB-4, a noninvasive and easily applicable liver fibrosis index, as a risk factor for HCC incidence among alcohol drinkers without viral hepatitis.
This retrospective cohort study included 6661 generally healthy adults who were 30 years old or older, did not have chronic viral hepatitis, and visited Seoul National University Hospital for a general, routine health evaluation. The future HCC incidence was determined from National Health Insurance medical service claims data (median follow-up, 6.2 years).
With adjustments for age, sex, body mass index, smoking, and alcohol, compared with subjects with FIB-4 values less 1.00, subjects with FIB-4 values greater than or equal to 1.75 and less than 2.10 and subjects with FIB-4 values greater than or equal to 2.10 had adjusted hazard ratios (aHRs) of 5.18 (95% confidence interval [CI], 1.12-24.00) and 13.63 (95% CI, 3.77-49.33), respectively, for HCC incidence. This was heightened in subjects who drank more 30 g of alcohol per day: the aHRs were 8.39 (95% CI, 1.28-54.87) and 16.58 (95% CI, 3.87-71.04), respectively. FIB-4 was shown to have a higher predictive value for HCC incidence than ultrasonographically detected liver cirrhosis (C-index, 0.665 vs 0.527; P = .044).
High FIB-4 is a risk factor with a high predictive value for HCC incidence, especially among moderate to heavy alcoholics (>30 g/d). FIB-4 is a readily available and probably cost-effective clinical tool with potential value for identifying subpopulations of alcoholics at particularly high risk who would benefit from regular HCC screening. Further investigations are warranted to validate our results; nonetheless, our study suggests that FIB-4 may be useful in HCC screening among alcoholics.
尽管重度酗酒者患肝细胞癌(HCC)的风险增加,但尚无指南推荐对重度酗酒者进行HCC筛查。本研究调查了FIB-4,一种非侵入性且易于应用的肝纤维化指标,作为无病毒性肝炎的饮酒者中HCC发病的危险因素。
这项回顾性队列研究纳入了6661名30岁及以上的一般健康成年人,他们没有慢性病毒性肝炎,并前往首尔国立大学医院进行一般常规健康评估。未来HCC发病率由国民健康保险医疗服务理赔数据确定(中位随访时间为6.2年)。
在对年龄、性别、体重指数、吸烟和饮酒进行调整后,与FIB-4值小于1.00的受试者相比,FIB-4值大于或等于1.75且小于2.10以及FIB-4值大于或等于2.10的受试者发生HCC的调整后风险比(aHRs)分别为5.18(95%置信区间[CI],1.12 - 24.00)和13.63(95%CI,3.77 - 49.33)。在每天饮酒超过30克的受试者中,这种风险增加:aHRs分别为8.39(95%CI,1.28 - 54.87)和16.58(95%CI,3.87 - 71.04)。结果显示,FIB-4对HCC发病率的预测价值高于超声检测到的肝硬化(C指数,0.665对0.527;P = 0.044)。
高FIB-4是HCC发病的一个具有高预测价值的危险因素,尤其是在中度至重度酗酒者(>30克/天)中。FIB-4是一种易于获得且可能具有成本效益的临床工具,对于识别受益于定期HCC筛查的特别高危酗酒亚人群具有潜在价值。有必要进行进一步研究以验证我们的结果;尽管如此,我们的研究表明FIB-4可能有助于酗酒者的HCC筛查。